Momenta Pharmaceuticals, Inc.
Jun 7, 2017

Momenta Pharmaceuticals to Webcast Presentation at the Goldman Sachs 38th Annual Global Healthcare Conference

CAMBRIDGE, Mass., June 07, 2017 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that it will provide a corporate overview, including an update on the timing of regulatory submissions for marketing approval for M923, its biosimilar HUMIRA® (adalimumab) candidate, at the Goldman Sachs 38th Annual Global Healthcare Conference. The presentation is scheduled for Wednesday, June 14th at 11:20 a.m. PT/2:20 p.m. ET.

A webcast of the presentation will be available live on the "Investors" section of the company's website located at www.momentapharma.com.  A replay of the presentation will be posted on the Momenta website approximately one hour after the event.

About Momenta
Momenta Pharmaceuticals is a biotechnology company specializing in the detailed structural analysis of complex drugs and is headquartered in Cambridge, MA. Momenta is applying its technology to the development of generic versions of complex drugs, biosimilar and potentially interchangeable biologics, and to the discovery and development of novel therapeutics for autoimmune indications.

To receive additional information about Momenta, please visit the website at www.momentapharma.com, which does not form a part of this press release.

Our logo, trademarks, and service marks are the property of Momenta Pharmaceuticals, Inc. All other trade names, trademarks, or service marks are property of their respective owners.

Forward-Looking Statements
Statements in this press release regarding management's future expectations, beliefs, intentions, goals, strategies, plans or prospects, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including but not limited to statements regarding providing a corporate overview and updating the timing of regulatory submissions. Forward-looking statements may be identified by words such as "believe," "continue," "could," "expect," "guidance," "may," "plan," "potential," "target," "will" and other similar words or expressions, or the negative of these words or similar words or expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, including those referred to under the section "Risk Factors" in the Company's Quarterly Report on Form 10-Q for the year ended March 31, 2017, filed with the Securities and Exchange Commission, as well as other documents that may be filed by the Company from time to time with the Securities and Exchange Commission. As a result of such risks, uncertainties and factors, the Company's actual results may differ materially from any future results, performance or achievements discussed in or implied by the forward-looking statements contained herein. The Company is providing the information in this press release as of this date and assumes no obligations to update the information included in this press release or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Sarah Carmody

Momenta Pharmaceuticals

1-617-395-5189

IR@momentapharma.com

Primary Logo

Source: Momenta Pharmaceuticals, Inc.

News Provided by Acquire Media